Applications
ELISA
SPR Analysis
Antibody Discovery
Antibody Screening
Immunization
PD/PK
Virus-like Particle (VLP)-Displayed Antigens
Research and development for antibody drugs has increasingly fierce competition. The discovery of antibodies specific to difficult targets can help you maintain competitiveness in the market.
What are VLP-displayed antigens?
Nanoparticles (20-200nm) derived from outer capsid protein of virus
Formed by the automatic assembly of one or more viral capsid proteins
Surface display provides multiple copies of antigen per VLP to enhance immunogenicity
Why use VLP-displayed antigens?
Do not contain viral infectious genomes, making them safe to use in manufacturing operations
Efficiently activate the body’s humoral and cellular immune responses
Natural configuration of transmembrane proteins for discovery of differentiated antibodies
Advantages
Transmembrane proteins
High activity
High immunogenicity
Soluble expression of different proteins
Clear structure
Not pathogenic
Validation Data
Figure 1. Fluorescent Human Claudin 18.2 VLP used to detect the positive rate of anti-Claudin 18.2 CAR 293T cells.
Figure 2. Immobilized Human GPRC5D VLP at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 11.8ng/ml determined by ELISA.
Figure 3. Biotinylated Human Claudin 6 VLP captured on CM5 Chip via Streptavidin can bind Anti-Claudin6 Antibody with an affinity constant of 0.65 nM as determined in SPR assay (Biacore T200).
Figure 4. The purity of Human SSTR2 VLP is greater than 95% as determined by SEC-HPLC.
Custom Projects
Let us know if you're looking for a VLP or modification not listed on our site. KACTUS can provide customization of VLP-displayed antigens.